TABLE 5.
Liver-related outcomes in women with AH and pregnancy compared to no pregnancy (30–3600)
| Variable | AH + subsequent pregnancy (n=499) | AH - no subsequent pregnancy (n=499) | P |
|---|---|---|---|
| Demographics | |||
| Age*, mean±SD | 31.6±4.6 | 31.6±4.6 | 0.983 |
| Body mass index, mean±SD | 26.3±6.6 | 26.4±7.3 | 0.935 |
| White*, % | 71.1 | 71.1 | 1.000 |
| Black or African American*, % | 11.8 | 11.6 | 0.922 |
| Hispanic or Latino*, % | 10.2 | 9.8 | 0.833 |
| Asian*, % | 2.0 | 2.0 | 1.000 |
| Baseline AH labs, mean±SD | |||
| ALT (U/L) | 78.6±143.6 | 81.6±108.7 | 0.787 |
| AST (U/L) | 130.7±139.9 | 143.4±139.2 | 0.288 |
| ALP (U/L) | 121.4±73.3 | 138.5±104.3 | 0.025 |
| Bilirubin, total (mg/dL) | 1.9±3.4 | 3.0±5.1 | 0.003 |
| Creatinine (mg/dL) | 0.7±0.3 | 0.6±0.3 | 0.553 |
| MAT prescriptions (3-year) | |||
| Acamprosate, % | 9.2 | 10.2 | 0.833 |
| Naltrexone, % | 16.6 | 12.6 | 0.073 |
| Disulfiram, % | 4.0 | 3.4 | 0.615 |
| Topiramate, % | 3.8 | 2.6 | 0.218 |
| Baclofen, % | 3.6 | 3.2 | 0.727 |
| Gabapentin, % | 37.3 | 31.7 | 0.062 |
| Any medication, % | 29.7 | 25.0 | 0.102 |
| Any medication + gabapentin, % | 49.8 | 41.8 | 0.010 |
| Liver-related outcomes (10-year) | |||
| Cirrhosis—all, % | 31.1 | 32.5 | 0.634 |
| Cirrhosis—new, % | 18.1 | 19.4 | 0.639 |
| Ascites—all, % | 23.4 | 27.5 | 0.146 |
| Ascites—new, % | 9.1 | 9.6 | 0.796 |
| Bleeding varices, % | 5.8 | 4.4 | 0.314 |
| HE, % | 9.6 | 11.4 | 0.353 |
| Spontaneous bacterial peritonitis, % | 4.0 | 6.0 | 0.147 |
| Hepatorenal syndrome, % | 3.6 | 6.2 | 0.047 |
| Composite decompensationa, % | 21.2 | 24.4 | 0.227 |
| Mortality | |||
| Deceased, 3 y, % | 2.8 | 10.8 | <0.001 |
| Deceased, 10 y, % | 4.8 | 19.0 | <0.001 |
| Deceased, 30–10 y | 4.8 | 12.3 | <0.001 |
a
Includes any of the following: ascites, varices with bleeding, HE.
*
indicates demographic variables included in propensity score matching; additional matched variables included obesity diagnosis and prior live birth
Abbreviation: AH, alcohol-associated hepatitis.